The telehealth sector’s reliance on seamless subscription models for growth has come under scrutiny as difficulties in cancelling these subscriptions have led consumers to seek chargebacks through their credit card providers. This trend prompted Visa Inc. to place Hims & Hers Health into its Acquirer Monitoring Program after a significant increase in billing disputes. This program imposes a financial penalty for each contested transaction, threatening the revenue structure of the telehealth provider.
At the heart of this issue are allegations made by the Federal Trade Commission, in conjunction with the attorneys general of California and Utah, claiming that Hims & Hers Health engaged in deceptive billing practices that obscured the cancellation process for users. When users find it challenging to halt recurring charges, they resort to filing chargebacks. Visa’s response to the heightened dispute activity has resulted in penalties amounting to approximately $75,000 in a recent month alone.
Investor concerns are growing as Hims & Hers Health faced a decline in gross margins and revised earnings guidance fell below analyst expectations. To exit Visa’s penalty program, the company must reduce its chargeback rate—a challenge that may slow down its customer acquisition efforts, thereby impacting growth.
Despite these challenges, Hims & Hers Health could benefit from its expansion into compounded GLP-1 weight-loss peptides, a segment with significant revenue potential. If regulatory conditions improve or if the company can scale its offerings effectively, the resulting growth might outweigh the financial penalties imposed by Visa.
Why this story matters
- It highlights vulnerabilities in the telehealth industry, particularly concerning subscription practices and regulatory compliance.
Key takeaway
- Hims & Hers Health faces challenges balancing consumer acquisition with regulatory scrutiny, impacting financial performance.
Opposing viewpoint
- While current issues are significant, there is strong potential for growth in the company’s peptide market that could mitigate financial penalties.
